{"id":"noopept","name":"Noopept (omberacetam)","aliases":["omberacetam","GVS-111","N-phenylacetyl-L-prolylglycine ethyl ester","Noopept"],"url":"https://lyoresearch.com/compounds/noopept","class":{"id":"nootropic-peptides","name":"Nootropic and sleep peptides","url":"https://lyoresearch.com/classes/nootropic-peptides"},"summary":"Noopept is a synthetic molecule built from the dipeptide proline-glycine, developed at the Zakusov Institute in Moscow and registered in Russia as a nootropic for mild cognitive impairment after brain injury or stroke. Outside Russia it is not approved anywhere. The human evidence is a single Russian comparison against piracetam in patients with vascular or traumatic cognitive impairment; its English translation carries no abstract in PubMed, and no independent group has replicated it. The claims made for it in healthy people — focus, memory, learning — have never been tested in a controlled trial.","overall_grade":"D","overall_grade_meaning":"no human evidence","human_trials":"1 Russian comparative trial vs piracetam (2008); no independent replication","regulatory_status":"Not approved (outside Russia)","molecule":{"formula":"C17H22N2O4","molecular_weight":"318.4","cas":"157115-85-0","pubchem_cid":180496,"note":null},"pharmacokinetics":{"basis":"animal","route":"Oral","half_life":"No human pharmacokinetic data; rat studies only","licensed_regimen":null,"product":null,"source":{"title":"Boiko SS, et al. Pharmacokinetics of new nootropic acylprolyldipeptide and its penetration across the blood-brain barrier after oral administration. Bull Exp Biol Med 2000","url":"https://pubmed.ncbi.nlm.nih.gov/10977920/"}},"outcomes":[{"outcome":"Cognitive impairment after brain injury or stroke","grade":"D","grade_meaning":"no human evidence","effect_size":"not measurable","adverse":false,"human_studies":"1 Russian comparative trial (vs piracetam)","evidence":"The basis of the Russian registration. Published in Russian in 2008 and in translation in 2009; the indexed record has no abstract, so the size, blinding and outcome measures cannot be assessed from the international literature. Not replicated.","references":[{"citation":"Neznamov GG, Teleshova ES. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin.","where":"Neurosci Behav Physiol, 2009","url":"https://pubmed.ncbi.nlm.nih.gov/19234797/"},{"citation":"Neznamov GG, Teleshova ES. [A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment in patients with organic brain diseases of vascular and traumatic origin].","where":"Zh Nevrol Psikhiatr Im S S Korsakova, 2008 (Russian)","url":"https://pubmed.ncbi.nlm.nih.gov/18697252/"}]},{"outcome":"Cognition in healthy people","grade":"D","grade_meaning":"no human evidence","effect_size":"not measurable","adverse":false,"human_studies":"None","evidence":"The nootropic use it is sold for. No controlled human study.","references":[{"citation":"Searches of PubMed and trial registries for omberacetam / Noopept in healthy volunteers.","where":"LYO literature search, September 2026","url":"https://pubmed.ncbi.nlm.nih.gov/?term=noopept+OR+omberacetam+healthy+volunteers+randomized"}]},{"outcome":"Anxiety","grade":"D","grade_meaning":"no human evidence","effect_size":"not measurable","adverse":false,"human_studies":"None controlled","evidence":"Anxiolytic effects are reported in the Russian literature and in rodents; no controlled human trial.","references":[]},{"outcome":"Safety in humans","grade":"D","grade_meaning":"no human evidence","effect_size":"not measurable","adverse":true,"human_studies":"No systematic international data","evidence":"Reported as well tolerated in Russian use. No pharmacovigilance dataset outside Russia; no data on long-term use.","references":[]}],"regions":[{"region":"European Union","status":"Unauthorised medicinal product","note":"No marketing authorisation in any member state. Sold online as a 'supplement', which it is not."},{"region":"United States","status":"Not approved","note":"Not an approved drug and not a lawful dietary-supplement ingredient."},{"region":"United Kingdom","status":"Unlicensed medicine","note":"No MHRA licence; supply for human use is an offence."},{"region":"Australia","status":"Prescription-only / unapproved","note":"Not on the ARTG; imports are seized."},{"region":"Canada","status":"Not authorised","note":"No Drug Identification Number."},{"region":"Sport (WADA)","status":"Not on the list","note":"Not named on the Prohibited List."}],"faq":[{"q":"Is Noopept approved anywhere?","a":"In Russia, since 2007, for cognitive impairment after brain injury or stroke. Not in the EU, US, UK, Australia or Canada."},{"q":"Does Noopept improve memory or focus?","a":"There is no controlled trial in healthy people. The one clinical study is in patients with brain injury or stroke, published in Russian, and cannot be evaluated from the indexed literature."},{"q":"Is Noopept a peptide?","a":"It is built from a dipeptide and often called a 'peptide nootropic', but it is a small synthetic ester. Its proposed active metabolite, cycloprolylglycine, is a true dipeptide."}],"references":[{"cite":"Neznamov GG, Teleshova ES. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin.","where":"Neurosci Behav Physiol, 2009","url":"https://pubmed.ncbi.nlm.nih.gov/19234797/","note":"Translation of the 2008 Russian paper. No abstract available in PubMed."},{"cite":"Neznamov GG, Teleshova ES. [A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment in patients with organic brain diseases of vascular and traumatic origin].","where":"Zh Nevrol Psikhiatr Im S S Korsakova, 2008 (Russian)","url":"https://pubmed.ncbi.nlm.nih.gov/18697252/","note":"Original Russian-language report."},{"cite":"Searches of PubMed and trial registries for omberacetam / Noopept in healthy volunteers.","where":"LYO literature search, September 2026","url":"https://pubmed.ncbi.nlm.nih.gov/?term=noopept+OR+omberacetam+healthy+volunteers+randomized","note":"No controlled trial identified."}],"last_reviewed":"2026-09-10","literature_searched_to":"2026-09-10","changelog":[{"date":"2026-09-10","note":"Initial publication. Grade D throughout: one unreplicated Russian trial without an indexed abstract."}],"license":"CC BY 4.0 — cite as “LYO Research” with a link.","methodology":"https://lyoresearch.com/methodology"}